On July 7, Eli Lilly rose 3.08% in pre-market trading, trading at $1,235.0/share, with turnover of $22.23 million.

On the news front, JPMorgan raised its target price on Eli Lilly from $1,300 to $1,400, implying approximately 17% upside from the current level. Analyst Chris Schott expects total quarterly sales of approximately $20.7 billion and EPS of $8.85, both above consensus estimates, driven by Mounjaro's continued international volume growth and steady U.S. obesity market expansion. Cantor Fitzgerald also lifted its target from $1,230 to $1,350.

Additionally, Health Canada approved Mounjaro (tirzepatide) for the treatment of type 2 diabetes in pediatric patients aged 10 and older, further broadening the drug's addressable population. The company's next earnings report is scheduled for August 5, with consensus EPS expected at $8.98.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)